Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry G Bone

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
The Lancet. Diabetes & Endocrinology|May 27, 2017
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extensionHenry G Bone, Rachel B Wagman, Maria L Brandi, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 25, 2011
Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extensionSocrates Papapoulos, Roland Chapurlat, Cesar Libanati, et al.
The Journal of Clinical Endocrinology and Metabolism|August 28, 2013
The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extensionHenry G Bone, Roland Chapurlat, Maria-Luisa Brandi, et al.
The Journal of Clinical Endocrinology and Metabolism|January 22, 2015
A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trialBente L Langdahl, Christence Stubbe Teglbjærg, Pei-Ran Ho, et al.
The Journal of Clinical Endocrinology and Metabolism|June 23, 2012
A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral densityEric Orwoll, Christence S Teglbjærg, Bente L Langdahl, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
The Lancet. Diabetes & Endocrinology|May 27, 2017
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extensionHenry G Bone, Rachel B Wagman, Maria L Brandi, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 25, 2011
Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extensionSocrates Papapoulos, Roland Chapurlat, Cesar Libanati, et al.
The Journal of Clinical Endocrinology and Metabolism|August 28, 2013
The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extensionHenry G Bone, Roland Chapurlat, Maria-Luisa Brandi, et al.
The Journal of Clinical Endocrinology and Metabolism|January 22, 2015
A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trialBente L Langdahl, Christence Stubbe Teglbjærg, Pei-Ran Ho, et al.
The Journal of Clinical Endocrinology and Metabolism|June 23, 2012
A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral densityEric Orwoll, Christence S Teglbjærg, Bente L Langdahl, et al.
Pageof 6